Conclusions
hemorrhage
HEMORRHAGE, DISEASE, METASTASIS
In this phase II nonrandomized controlled trial, no grade 4 hemorrhage or grade 5 AEs were reported with the addition of bevacizumab to CCRT for locally or regionally advanced NPC. The relatively low rate of distant metastasis despite nearly 90% of patients presenting with stage III to IVB disease is intriguing and may warrant further investigation. Given that 20% of patients died from disease,